Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers
SANIBA
Effectiveness and Safety of an Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers of the Fore Foot: a Prospective Randomised Pilot Study
1 other identifier
interventional
33
1 country
1
Brief Summary
It's a pilot prospective opened multicentric randomised study. We measure the efficiency and the safety of a new concept of off-loading shoe (SANIDIAB) compared with an old one (BAROUK) to treat chronic diabetic foot ulcer which involved a high risks of amputation 64 diabetic patients with a plantar neuropathic ulcer of the fore foot without infection, osteomyelitis or angiopathy, will be included. 32 patients will be treated with SANIDIAB shoe and 32 with BAROUK shoe
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3 diabetes-mellitus
Started Jun 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2011
CompletedFirst Submitted
Initial submission to the registry
April 25, 2012
CompletedFirst Posted
Study publicly available on registry
April 26, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedNovember 14, 2013
May 1, 2013
1.7 years
April 25, 2012
November 13, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Healing duration of the diabetic foot ulcer
6 months
Secondary Outcomes (3)
Rate of reulceration
6 months
Rate of amputation
6 months
Compliance of patients to footwear
6 months
Study Arms (2)
barouk
ACTIVE COMPARATORsanidiab
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- More of 18 years old man or woman
- Type 1 or 2 Diabetes mellitus
- A new plantar ulcer of the fore foot or the toes
- GRADE 1A or 2 A of the University of Texas Classification
- Neuropathy assessed by absence of sensation in 10g monofilament test
You may not qualify if:
- Severe angiopathy (Grade 3 of the PEDIS classification)
- Osteomyelitis or cellulitis of the foot
- Transmetatarsal amputation
- Other study in course
- Immunosuppressive drugs, antibiotic therapy,
- Hepatic insufficiency
- No possibility to follow the patients every 14 days
- No state health insurance
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Assistance Publique - Hôpitaux de Parislead
- MAYZAUDcollaborator
Study Sites (1)
Groupe hospitalier Pitié-Salpêtrière
Paris, 75013, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Georges HA VAN, MD
APHP
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2012
First Posted
April 26, 2012
Study Start
June 1, 2011
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
November 14, 2013
Record last verified: 2013-05